Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas(†)

BACKGROUND: In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission tomography (PET) and to compare metabolic response rates a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J.-L., Liu, H., McGovern, D., Lu, B., Von Hoff, D. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803456/
https://www.ncbi.nlm.nih.gov/pubmed/26802153
http://dx.doi.org/10.1093/annonc/mdw020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803456/
https://www.ncbi.nlm.nih.gov/pubmed/26802153
http://dx.doi.org/10.1093/annonc/mdw020

Ejemplares similares